Search

Displaying results 91 - 100 of 6079 in total
  1. Drug

    Isavuconazole

    go.drugbank.com/drugs/DB11633
    ApprovedInvestigational

    has a potential for nephrotoxicity [A32029]. … Invasive fungal infections pose significant clinical challenges for patients, especially those who are immunocompromised.

    Categories: Antimycotics for Systemic Use, Antiinfectives for Systemic UseProducts: CRESEMBA (POWDER FOR SOLUTION FOR CONCENTRATE FOR SOLUTION FOR INFUSION 200 MG/VIAL)
  2. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures [FDA Label]. … Epoetin alfa biosimilar, such as Retacrit (epoetin alfa-epbx or epoetin zeta), has been formulated to allow more access to treatment options for patients in the market [L2784].

    Products: FER, FER
  3. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    [L12621,L12627] Durvalumab is marketed under the brand name Imfinzi, which is available for intravenous injections. … Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody and a novel immune-checkpoint inhibitor for cancer treatment.

    Products: IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/ML, IMFINZI CONCENTRATE FOR SOLUTION FOR INTRAVENOUS INFUSION 50 MG/ML
  4. Drug

    Omalizumab

    go.drugbank.com/drugs/DB00043
    ApprovedInvestigational

    Omalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE). IgE promotes the release of inflammatory mediators from mast cells and basophils during allergic and inflammatory reacti...

    Products: Xolair 75mg Powder and Solvent for Solution for Injection, Xolair 150mg Powder and Solvent for Solution for Injection
  5. Drug

    Olipudase alfa

    go.drugbank.com/drugs/DB12835
    ApprovedInvestigational

    [A251590] It is the first and only enzyme replacement therapy in the world for the treatment of Acid Sphingomyelinase Deficiency (ASMD), also known as Niemann–Pick disease.

    Products: XENPOZYME 20MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION
  6. Drug

    Enoxaparin

    go.drugbank.com/drugs/DB01225
    ApprovedInvestigational

    Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection an...

    Products: ./0.6ML FER, ./0.8ML FER
  7. Drug

    Paclitaxel

    go.drugbank.com/drugs/DB01229
    ApprovedInvestigationalVet approved

    It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. … Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel

    Synonyms: Paclitaxel protein-bound particles for injection suspensionProducts: Aclipak Concentrate for Solution for Infusion 6mg/ ml, FONKOPAC CONCENTRATE FOR SOLUTION FOR INFUSION 6MG/ML
  8. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    candidates for cytotoxic chemotherapy [A98]. … It is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory) [L941].

    Products: MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/VIAL
  9. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer in September 2011 and in men with osteoporosis at high risk for fracture in September 2012. … It further received additional indication approval to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer and women at high risk

    Categories: Drugs for Treatment of Bone DiseasesProducts: XGEVA 120mg Solution for Injection, XGEVA Solution for Injection 120 mg/vial
  10. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    In order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … ranibizumab first began after [bevacizumab], another anti-VEGF anticancer drug, was discovered to inhibit neovascularization and used in the off-label treatment of neovascular age-related macular degeneration for

    Products: Lucentis 10mg/ml Solution for Injection, ACCENTRIX 10MG/ML SOLUTION FOR INJECTION